Table II.
Medication use and laboratory values
| Medication class | No. (%) |
|---|---|
|
Nonaspirin antiplatelets |
30,120 (17.1) |
| Any statins | 106,949 (60.8) |
| High-intensity statin | 61,371 (34.9) |
| Any claudication drugs | 7168 (4.1) |
| Pentoxifylline | 2250 (1.3) |
| Cilostazol | 5054 (2.9) |
| Smoking cessation therapy | 12,723 (7.2) |
| Varenicline | 1341 (0.8) |
| Nicotine patches or gums |
11,592 (6.6) |
| Laboratory values | Median (IQR) |
|
Total cholesterol |
158 (135–186) |
| LDL cholesterol | 87.5 (69–111) |
| Non-HDL cholesterol | 39 (32.2–48) |
| Hemoglobin A1c in diabetics | 7.1 (6.4–8.2) |
HDL, High-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein.
High-intensity statin therapy was defined as simvastatin 80 mg, ator-vastatin 40 to 80 mg, or rosuvastatin 20 to 40 mg. The sample size for data regarding laboratory values was as follows: total cholesterol, 151,641 patients; LDL cholesterol, 150,896 patients; non-HDL cholesterol, 151,023 patients; and hemoglobin A1c in diabetics, 75,437 patients.